 MicroCloud Hologram Inc. (NASDAQ:HOLO) (“HOLO” or the “Company”), a Hologram Digital Twins Technology provider, today announced the launch of its holographic BCI (Brain-Computer Interface) data acquisition system. The system is the result of the Company’s independent research and development, which is conducive to further improving the Company’s intellectual property protection system, maintaining its technological leadership, and enhancing its core competitiveness.
Celyad Oncology Announced FDA Lifted Clinical Hold of CYAD-101-002 Phase 1b Trial
Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ: CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the U.S.
